Order byBest matchMost fresh
Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data
Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.
Lohud.com, Westchester County on MSN1d
Regeneron to acquire 23andMe DNA testing firm. How that could impact your genetic data
Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know
Daily Voice on MSN13h
Westchester-Based Regeneron Buying Bankrupt 23andMe For $256M, Pledges To Protect DNA Data
Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services with no changes.
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.
Stocktwits on MSN1d
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts
Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology company 23andMe Holding Co. for $256 million. Regeneron intends to acquire 23andMe’s Personal Genome Service (PGS),
Feedback